FDA Giving Priority Review to Oxbryta in Treating Children, 4-11

FDA Giving Priority Review to Oxbryta in Treating Children, 4-11

305451

FDA Giving Priority Review to Oxbryta in Treating Children, 4-11

The U.S. Food and Drug Administration (FDA) has agreed to consider Global Blood Therapeutics’ (GBT) request to expand the use of Oxbryta (voxelotor) to children as young as 4 with sickle cell disease (SCD). The oral therapy is currently conditionally approved — when given at a daily dose of 1,500 mg — to treat SCD patients ages 12 and older. In a separate application, also now under FDA review, the company is asking for approval of a…

You must be logged in to read/download the full post.